TT
Therapeutic Areas
Sanofi Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Amlitelimab | Moderate-to-Severe Atopic Dermatitis | Phase 3 |
| Sarclisa (Isatuximab) SC | Multiple Myeloma | Regulatory (EU) |
| Rezurock (Belumosudil) | Chronic Graft-vs-Host Disease | Approved (EU) |
| Dupixent (Dupilumab) | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 |
| Tolebrutinib | Multiple Sclerosis | Phase 3 |
| Frexalimab | Multiple Sclerosis | Phase 3 |
| SAR443820 (Rilzabrutinib) | Immune Thrombocytopenia (ITP) | Phase 3 |
| SAR441566 | Solid Tumors | Phase 1/2 |